Sign inJoin waitlistJoin the waitlist

Comron Hassanzadeh

Associate Program Director, Radiation Oncology Residency · University of Texas M D Anderson Cancer Center

Credentials: · · · · ·

History

Radiation Oncology Residency · University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

Radiation Oncology
Washington University School of Medicine
2018–2022
Mercy Hospital
2017–2018
University of Missouri–Kansas City School of Medicine
2013–2017

Research

Refining Patient Selection for Reirradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-institution Cohort Study by the MIRI Collaborative
International journal of radiation oncology · 2018 · 133 citations
Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation
Advances in Radiation Oncology · 2021 · First of 12 authors · 113 citations
Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-institution Analysis
International journal of radiation oncology · 2018 · 67 citations

Chad Tang
13 papers
OM
Osama Mohamad
13 papers
Karen Hoffman
9 papers
Seungtaek Choi
9 papers
Henry Mok
8 papers
Steven Frank
8 papers
Quynh-Nhu Nguyen
7 papers
Sean McGuire
7 papers
Ryan Park
6 papers · 1 as a resident
Michael Rooney
5 papers · 5 as a fellow
Ramez Kouzy
5 papers · 5 as a resident
Shalin Shah
5 papers

Clinical trials

Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)
Principal investigator · Recruiting · Phase 1, Phase 2
M.D. Anderson Cancer Center
2024–2027
PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer.
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2024–2027
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Site PI · Recruiting · Phase 3
NRG Oncology
2025–2035